Jefferies fears renewed pressure on Novo Nordisk's growth
Financial analyst Jefferies predicts that Novo Nordisk will be subjected to heated price competition when the patent on obesity medication Victoza expires in a few years. Novo Nordisk does not agree with this risk assessment.
BY ANDREAS LØNSTRUP, TRANSLATED BY NIELSINE NIELSEN
Five years ago, insulin prices were under such high pressure that Novo Nordisk had to downgrade its guidance multiple times, resulting in grave share price declines. The financial analyst Jefferies predicts Novo's growth engine with GLP-1 medication may encounter a similar type of pressure after 2023-24, when the patent for Novo Nordisk's first big seller in the GLP-1 series, Victoza, expires, according to Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
